{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:03:20Z","timestamp":1770498200433,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1995,6,1]],"date-time":"1995-06-01T00:00:00Z","timestamp":801964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[1995,6]]},"DOI":"10.1016\/0959-8049(94)00459-5","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T11:42:39Z","timestamp":1027597359000},"page":"876-881","source":"Crossref","is-referenced-by-count":48,"title":["Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-\u03b1 after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen"],"prefix":"10.1016","volume":"31","author":[{"given":"J.","family":"Atzpodien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lopez H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Franzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"K\u00f6rfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Volkenandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Duensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schomburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chaitchik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Poliwoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0959-8049(94)00459-5_BIB1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000224680","article-title":"Combination phase I\u2013II study of imidazole carboxamide (NCS 45388)","volume":"26","author":"Wagner","year":"1971","journal-title":"Oncology"},{"key":"10.1016\/0959-8049(94)00459-5_BIB2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1097-0142(197709)40:3<1010::AID-CNCR2820400308>3.0.CO;2-C","article-title":"Results with methyl-CCNU and DTIC in metastatic melanoma","volume":"40","author":"Costanza","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/0959-8049(94)00459-5_BIB3","first-page":"787","article-title":"Phase II evaluation of 1,3,-bis(2chloroethyl-nitrosurea) (BCNU; NSC-409962) in patients with solid tumors","volume":"56","author":"Ramirez","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/0959-8049(94)00459-5_BIB4","first-page":"31","article-title":"Cisplatin hydration with and withour mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study","volume":"66","author":"Al-Sarraf","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/0959-8049(94)00459-5_BIB5","first-page":"171","article-title":"Phase II trial of carboplatin in advanced malignant melanoma","volume":"71","author":"Evans","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/0959-8049(94)00459-5_BIB6","first-page":"246","article-title":"Phase II trial of carboplatin versus iproplatin in disseminated malignant melanoma","volume":"7","author":"Verschraegen","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/0959-8049(94)00459-5_BIB7","first-page":"1403","article-title":"Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma","volume":"68","author":"Del Prete","year":"1984","journal-title":"Cancer Treat Rep"},{"issue":"12","key":"10.1016\/0959-8049(94)00459-5_BIB8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/0959-8049(94)00459-5_BIB9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/0140-6736(90)93039-R","article-title":"Home therapy with recombinant interleukin-2 and interferon-\u03b12b in advanced human malignancies","volume":"335","author":"Atzpodien","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/0959-8049(94)00459-5_BIB10","first-page":"639","article-title":"Enhancement of natural killer cytotoxicity bycisdiamminedichloroplatinum (II) in vivo and in vitro","volume":"46","author":"Lichtenstein","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(94)00459-5_BIB11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jnci\/82.2.139","article-title":"In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells","volume":"82","author":"Allavena","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/0959-8049(94)00459-5_BIB12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/0959-8049(94)00459-5_BIB13","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/1097-0142(19841215)54:12<2844::AID-CNCR2820541205>3.0.CO;2-Q","article-title":"Phase II study of recombinant leukocyte A interferon in disseminated malignant melanoma","volume":"54","author":"Creagan","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/0959-8049(94)00459-5_BIB14","first-page":"201","article-title":"Combined chemo- and immunotherapy using dacarbazine and continuous infusion of interleukin-2 in metastatic malignant melanoma. Results of a phase II clinical trial","volume":"1","author":"Dummer","year":"1991","journal-title":"Eur J Dermatol"},{"key":"10.1016\/0959-8049(94)00459-5_BIB15","first-page":"329","article-title":"Treatment of metastatic malignant melanoma with vinblastine, dacarbazine and cisplatin: a report from the cancer and leukemia group B","volume":"70","author":"Carey","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/0959-8049(94)00459-5_BIB16","first-page":"208","article-title":"DTIC and cis-platinum chemotherapy in metastatic malignant melanoma","volume":"6","author":"Oratz","year":"1987","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/0959-8049(94)00459-5_BIB17","first-page":"212","article-title":"DTIC-vindesine-cisplatin in disseminated malignant melanoma: a phase II study","volume":"6","author":"Ringborg","year":"1987","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/0959-8049(94)00459-5_BIB18","first-page":"997","article-title":"Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study","volume":"71","author":"Gunderson","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/0959-8049(94)00459-5_BIB19","first-page":"187","article-title":"A phase II study of dacarbazine, cisplatin, and outpatient interleukin-2 in metastatic malignant melanoma","volume":"9","author":"Flaherty","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/0959-8049(94)00459-5_BIB20","first-page":"157","article-title":"A phase II study of the treatment of metastatic malignant melanoma with combination of dacarbazine, cisplatin, interleukin-2 and alfa-interferon","volume":"27","author":"Hamblin","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/0959-8049(94)00459-5_BIB21","first-page":"293","article-title":"Biochemotherapy using interleukin-2 plus interferon-alfa 2a in combination with cisplatin, vinblastine and DTIC in advanced melanoma","volume":"10","author":"Leha","year":"1991","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0959804994004595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0959804994004595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T13:53:46Z","timestamp":1556718826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0959804994004595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,6]]}},"alternative-id":["0959804994004595"],"URL":"https:\/\/doi.org\/10.1016\/0959-8049(94)00459-5","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[1995,6]]}}}